Empyrean Neuroscience

Empyrean Neuroscience is a biopharma company that uses genetic engineering of fungi and plants to develop small molecule therapeutics for neuropsychiatric and neurologic disorders.

Using CRISPR/Cas9 and proprietary transformation technologies, the platform enables precise modulation of neuroactive compound production.

Its pipeline targets major depressive disorder, PTSD, substance abuse, and chronic pain, with programmes focused on fungal alkaloids, cannabinoids, and related molecules.